This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.
Varian Acquires humediQ, Boosts Motion Management Portfolio
by Zacks Equity Research
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Inogen (INGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 47.73% and 19.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
RTIX or INGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RTIX vs. INGN: Which Stock Is the Better Value Option?
LivaNova (LIVN) Soars: Stock Adds 10.4% in Session
by Zacks Equity Research
LivaNova (LIVN) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Integer Holdings (ITGR) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
Integer Holdings (ITGR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
by Zacks Equity Research
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
5 Profitable Stocks to Scoop Up Spectacular Returns
by Zacks Equity Research
Profitability analysis is one of the best tools to evaluate the future movement of a stock.
Stryker or Baxter: Which is a Better Pick for Your Portfolio?
by Zacks Equity Research
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for XHE
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
Why Is Inogen (INGN) Down 7% Since its Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Inogen (INGN) reports impressive Q4 financial results on the back of strong business-to-business and direct-to-consumer sales growth.
Healthcare, Vertex to Drive 3D Systems (DDD) Q4 Earnings?
by Zacks Equity Research
Strong prospects in 3D Systems' (DDD) healthcare business and Vertex brand are likely to prove conductive to its profitability in the to-be-reported quarter.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.